Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

(2021) Kelly E Dooley et al.   LANCET INFECTIOUS DISEASES

A pilot study of inflammatory mediators in brain extracellular fluid in paediatric TBM

(2021) Nicholas W. Loxton et al.   PLoS One

Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB

(2021) Precious Ngwalero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels

(2021) Arthur Hosmann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol

(2021) Armin Sebastian Guntner et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

(2021) Pauline Howell et al.   BMJ Case Reports

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

(2020) Francesca Conradie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis

(2019) Alvaro A. Ordonez et al.   ACS Infectious Diseases

The need for mathematical modelling of spatial drug distribution within the brain

(2019) Esmée Vendel et al.   Fluids and Barriers of the CNS

Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans

(2019) Elizabeth W. Tucker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis

(2019) Ming-Gui Wang et al.   BMC Pulmonary Medicine

The Global Neurological Burden of Tuberculosis

(2018) Mitashee Das et al.   SEMINARS IN NEUROLOGY

Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system

(2018) Annapurna Pamreddy et al.   RSC Advances

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2018) Nafees Ahmad et al.   LANCET

Improving Confidence in the Determination of Free Fraction for Highly Bound Drugs Using Bidirectional Equilibrium Dialysis

(2018) Yi-Chen Chen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Tuberculous meningitis

(2017) Robert J. Wilkinson et al.   Nature Reviews Neurology

Quantitation of Bedaquiline: Points of Attention: Table 1.

(2016) Tom Verhaeghe et al.   CLINICAL INFECTIOUS DISEASES

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

(2016) Lorenzo Guglielmetti et al.   EUROPEAN RESPIRATORY JOURNAL

In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis

(2016) N. Lounis et al.   MEDECINE ET MALADIES INFECTIEUSES

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

(2014) R. P. G. van Heeswijk et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

(2014) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

(2008) R. Rustomjee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY